Par Drugs And Chemicals peers

·UnclassifiedChart ›

Companies like Par Drugs And Chemicalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified
₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEAMcap ₹149 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
PAR
FY26
BALAXI
FY26
CROWN
FY26
STEELCITY
FY26
Peer
Average
Valuation — at last close
P/E11.33×75.81×13.60×◆ 8.15×32.52× -65%
P/B1.33×◆ 0.44×1.57×0.85×0.95× +39%
EV/EBITDA6.23×17.59×8.51×◆ 3.93×10.01× -38%
Market Cap₹149 Cr₹109 Cr₹122 Cr₹118 Cr₹116 Cr +28%
Growth
Revenue CAGR 3Y2.68%-7.05%◆ 27.25%4.48%8.23% -67%
Revenue CAGR 5Y—3.15%—◆ 3.53%3.34%
Net Income CAGR 3Y4.97%-68.64%◆ 31.51%8.43%-9.57% +152%
Revenue YoY (latest Q)-4.28%14.05%◆ 29.27%28.51%23.94% -118%
Net Income YoY (latest Q)-36.36%◆ 347.57%4.51%66.71%139.60% -126%
Profitability
EBITDA Margin16.53%3.16%◆ 52.72%26.84%27.57% -40%
Net Income Margin12.65%0.52%22.33%◆ 22.95%15.27% -17%
Return on Common Equity12.43%0.59%◆ 12.75%10.80%8.05% +54%
Return on Capital Employed◆ 12.30%2.40%10.27%11.64%8.10% +52%
Return on Assets◆ 10.55%0.44%4.51%6.33%3.76% +181%
Credit & Quality
Total Debt/Equity◆ 0.00×0.22×0.73×0.07×0.34× -100%
Interest Coverage◆ 105.48×1.63×3.06×17.51×7.40× +1325%
Scale — latest FY
Revenue / Total Income₹104 Cr₹270 Cr₹39.7 Cr₹62.3 Cr₹124 Cr -16%
Net Income₹13.1 Cr₹1.4 Cr₹8.9 Cr₹14.3 Cr₹8.2 Cr +60%
Total Assets₹129 Cr₹337 Cr₹215 Cr₹237 Cr₹263 Cr -51%
EPS₹10.65₹0.26₹7.72₹9.57₹5.85 +82%
Book Value per Share₹91.01₹45.12₹66.76₹91.35₹67.74 +34%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.